CagriSema

Fat LossInvestigational amylin + GLP-1 combinationEmerging

Also known as: Cagrilintide + semaglutide, NN9838 + semaglutide

CagriSema (also called Cagrilintide + semaglutide or NN9838 + semaglutide) is a research peptide in the GLP-1 Agonist class. CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): —
Half-life: —
FDA status: Investigational New Drug (IND)
Evidence level: Clinical Trial Evidence
Human dose established: Yes
Administration Route: Subcutaneous
Frequency: Once weekly
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026
Targets: GLP-1 receptorAmylin receptor

Vendor price snapshot

Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide: 2
Listed offers: 2
Price per mg: $14.90/mg

Open calculator · Compare vendors

Research summary

Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.

Research evidence

Regulatory review (FDA label)None in reviewed sources
Controlled human trials4 reviewed sources
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studiesNone in reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's CagriSema profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

CagriSema dosage evidence

CagriSema has no approved dosage. It is a fixed combination of cagrilintide and semaglutide, and human dosing comes from Novo Nordisk's phase 3 trials, which gave 2.4 mg of each under the skin once a week: in REDEFINE 1, mean weight change at 68 weeks was -20.4% against -3.0% with placebo in adults without diabetes. A lower 1.0 mg + 1.0 mg combination was also tested in type 2 diabetes.

Clinical Trial Evidence

Dosage evidence summary for CagriSema
Human dosing established	Yes
Studied dose range	1.0 mg or 2.4 mg of each component once weekly in phase 3 trials
Route	Subcutaneous
Frequency	Once weekly
Duration studied	40–68 weeks in the published phase 3 trials
Evidence level	Clinical Trial Evidence
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for CagriSema, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
REDEFINE 1 — phase 3a, overweight or obesity (NCT05567796)Clinical trial · Randomized, double-blind, placebo- and active-controlled phase 3a trial	Adults with obesity, or overweight with a related condition, without diabetes (n=3,417)	Cagrilintide 2.4 mg + semaglutide 2.4 mg (compared with each alone and placebo)	Subcutaneous	Once weekly	68 weeks	Mean body-weight change -20.4% with CagriSema against -3.0% with placebo; gastrointestinal events in 79.6% against 39.9%	Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025.
REDEFINE 2 — phase 3a, obesity with type 2 diabetes (NCT05394519)Clinical trial · Randomized, double-blind, placebo-controlled phase 3a trial	Adults with BMI ≥27, HbA1c 7–10% and type 2 diabetes (n=1,206)	Cagrilintide 2.4 mg + semaglutide 2.4 mg	Subcutaneous	Once weekly	68 weeks	Mean body-weight change -13.7% against -3.4% with placebo; HbA1c ≤6.5% reached by 73.5% against 15.9%	Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025.
REIMAGINE 1 — phase 3a, early type 2 diabetes (NCT06323174)Clinical trial · Randomized, double-blind, placebo-controlled phase 3a trial	Adults with type 2 diabetes on diet and exercise (n=189)	2.4 mg + 2.4 mg, or 1.0 mg + 1.0 mg	Subcutaneous	Once weekly	40 weeks	HbA1c change -1.8 points (2.4 mg each) and -1.5 points (1.0 mg each) against -0.1 with placebo; weight change -13.8% and -11.8% against -1.4%	Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol. 2026.
REIMAGINE 2 — phase 3, versus semaglutide or cagrilintide aloneClinical trial · Randomized, double-blind, placebo- and active-controlled phase 3 trial	Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor, BMI ≥25 (n=2,713)	2.4 mg + 2.4 mg, or 1.0 mg + 1.0 mg (compared with semaglutide alone, cagrilintide alone and placebo)	Subcutaneous	Once weekly	68 weeks	HbA1c change -1.91 points with CagriSema 2.4 mg each against -1.75 with semaglutide 2.4 mg alone (difference -0.16)	Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026.

Where sources disagree

CagriSema doses are given as the amount of each component: 2.4 mg + 2.4 mg means 2.4 mg of cagrilintide and 2.4 mg of semaglutide in the same weekly injection, 4.8 mg of peptide in total. The trials used a fixed-dose product, not two drugs measured separately.
Semaglutide 2.4 mg weekly is also the Wegovy maintenance dose, but CagriSema is not approved, and its trial results do not belong to semaglutide or cagrilintide alone; see the semaglutide and cagrilintide profiles for each on its own.
A vial labelled with one strength does not say how that amount is divided between the two compounds. The reconstitution figures below are for the labelled total only.

Reconstitution

Common research vial sizes: 10 mg.

Reconstitution arithmetic for CagriSema
Vial	Bacteriostatic water	Concentration	Per 0.01 mL
10 mg	2 mL	5 mg/mL	50 mcg per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

CagriSema dosage in published studies and labels →

Handling & administration

Injection Sites: AbdomenThigh
Timing Notes: Educational catalog only — not medical advice

Sequence & molecular data

Sequence and molecular data for CagriSema
Appearance	White lyophilized powder
Formulation	Lyophilized Powder

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection. The two act on separate satiety pathways: amylin signalling operates through amylin and calcitonin receptor complexes in the area postrema, while GLP-1 acts on its own receptors in the hypothalamus and brainstem. Because the pathways converge on food intake without sharing a receptor, the combination is intended to produce greater appetite suppression than either alone, and it is being studied to determine whether that translates into additive weight reduction.

Origin

Investigational combination of two peptides.

Targets

GLP-1 receptorAmylin receptor

Studies

Research statistics

43 PubMed publications · 23.3% human clinical research · 9 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

CagriSema has been studied under an Investigational New Drug application. It is not approved for marketing.

Regulatory and research status for CagriSema
FDA status	Investigational New Drug (IND)
Availability	Research-Only
WADA (sport)	Banned in Sport
Library classification	Clinical Trial

How FDA approval, compounding and research-only status differ

Benefits

Investigational dual-pathway obesity candidate

CagriSema side effects

The effects below are those reported in CagriSema clinical trials; long-term safety data may still be limited.

Side Effects

Nausea
Constipation
GI class effects

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

CagriSema: frequently asked questions

What is CagriSema?

Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.

How does CagriSema work?

Is CagriSema FDA approved?

No. CagriSema is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

Is CagriSema banned in sport?

CagriSema is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

What peptides are similar to CagriSema?

Compounds most often compared with CagriSema include Cagrilintide, Pramlintide, Petrelintide and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This CagriSema profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track CagriSema research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →